2024-512390-27-00CompletedPhase 1
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Apr 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 24 May 2024
- Start date
- 9 Jun 2023
- Lead sponsor
- Byondis B.V.
- Diseases
- Hodgkin lymphoma
- EU CT number
- 2024-512390-27-00
- EudraCT number
- 2022-002018-18
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 66
- 10 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Completed |
| Hospital Universitario HM Sanchinarro | Madrid | Spain | Completed |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Brescia | Italy | Completed |
| Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS | Candiolo | Italy | Completed |
| Ospedale San Raffaele S.r.l. | Milan | Italy | Completed |
| Istituto Europeo di Oncologia s.r.l | Milan | Italy | Completed |
| Azienda Unità Sanitaria Locale della Romagna | Ravenna | Italy | Completed |
| Stichting Amsterdam UMC | Amsterdam | Netherlands | Completed |
| Radboud Universitair Medisch Centrum (Radboudumc) | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.